A new combo drug is turning heads in diabetes care. Three phase 3 trials (REIMAGINE 1, 2, and 3) found that CagriSema — a once-weekly injectable combining cagrilintide and semaglutide — significantly cut HbA1c and body weight across different type 2 diabetes populations, from treatment-naive patients to those on basal insulin. Experts say it could signal a major shift in how T2D is managed.
A trio of phase 3 trials presented at the American Diabetes Association 2026 Scientific Sessions and published in The Lancet and Lancet Diabetes & Endocrinology show that CagriSema (cagrilintide + semaglutide, Novo Nordisk) delivers robust reductions in blood sugar and body weight across a wide range of type 2 diabetes (T2D) patients — from those newly diagnosed to those on long-term insulin therapy.
In REIMAGINE 1, treatment-naive T2D patients on the higher dose saw HbA1c drop by 1.8 percentage points and body weight fall by 13.8% over 40 weeks, versus just 0.1% and 1.4% with placebo. REIMAGINE 2 showed CagriSema outperformed semaglutide alone in patients on metformin ± SGLT2 inhibitors. REIMAGINE 3 demonstrated meaningful HbA1c and weight reductions even in patients on basal insulin — a notoriously hard-to-treat group. Safety profiles were consistent with the GLP-1 class, with mostly mild-to-moderate GI side effects and no severe hypoglycemia in REIMAGINE 1 or 3.
By the Numbers:
Why it matters: CagriSema could reshape T2D treatment by offering a single weekly injection that outperforms existing GLP-1 therapies on both glycemic control and weight loss — potentially reducing the need for additional medications and offering a new path for patients who struggle with insulin-based regimens.
